4Duan M, Zhou Z, Lin RX, et al. In vitro and in vivo protection against the highly pathogenic H5N1 influenza virus by an anti- sense phosphorothioate oligonucleotide. Antivir Ther, 2008, 13 (1) : 109-114.
5Cirino NM, Li G, Xiao W, et al. Targeting RNA decay with 2' ,5' oligoadenylate antisense in respiratory syncytial virus-infected ceils. Proc Nail Acad Sci USA, 1997, 94(5) : 1937- 1942.
6el-Awady MK, el-Din NG, el-Garf WT, et al. Antisense oligonucleotide inhibition of hepatitis C virus genotype 4 replication in HepG2 cells. Cancer Cell Int, 2006, 6: 18.
7Normand N, Valamanesh F, Savoldelli M, et al. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo. Mol Vis, 2005, 4(11) : 184-191.
8Morishita R, Kaneda Y, Ogihara T. Therapeutic potential of oligonucleotide-based therapy in cardiovascular disease. BioDrugs, 2003, 17(6) : 383-389.
9Coleman JR. The PB1-F2 protein of Influenza A virus: increasing pathogenicity by disrupting alveolar macrophages. Virol J, 2007, 4:9.
10Miyano-Kurosaki N, Bamor JS, Takeuchi H, et al. In vitro and in vivo transport and delivery of phosphorothioate oligonucleotides with cationic liposomes. Antivir Chem Chemother, 2004, 15 (2) : 93-100.
